文献速递免疫规划传染病防控与疫情报告

重组腺病毒5型载体埃博拉疫苗及同源初免-加强免疫在中国健康成人中的免疫持久性:随机双盲安慰剂对照1期试验最终报告

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
PubMed 文献 · Lancet Glob Health · 2016-12-23

在中国江苏一项随机双盲安慰剂对照1期试验中,120名18-60岁健康成人接种4·0×10^10或1·6×10^11病毒颗粒的腺病毒5型载体埃博拉疫苗或安慰剂,6个月后同源加强。初免后28天ELISA EC90 GMT低剂量组682·7、高剂量组1305·7,第168天分别降至197·9和575·5;加强后28天升至6110和11825。高剂量疫苗高度免疫原且安全,6个月同源加强可诱导更强更持久抗体反应。

要点

  • 初免后28天ELISA EC90 GMT低剂量组682·7(95%CI 424·3-1098·5),高剂量组1305·7(970·1-1757·2),安慰剂组5·0。
  • 第168天GMT低剂量组197·9(107·9-362·7),高剂量组575·5(394·8-838·8)。
  • 加强后28天GMT低剂量组6110(4705-7935),高剂量组11825(8904-15705)。

核心结论

  • 1·6×10^11病毒颗粒的腺病毒5型载体埃博拉疫苗高度免疫原且安全。
  • 4·0×10^10病毒颗粒低剂量也安全,但免疫原性似乎更易受腺病毒5型预存免疫影响。
  • 6个月间隔同源初免-加强可诱导更强、更持久抗体反应,支持加强接种以实现更持久保护的免疫策略。

研究设计与样本

  • 在中国江苏一个中心开展的随机、双盲、安慰剂对照1期临床试验,纳入120名18-60岁健康成人。
  • 初免肌内接种4·0×10^10病毒颗粒(低剂量,n=40)、1·6×10^11病毒颗粒(高剂量,n=40)或安慰剂(n=40,分两组各20),随访至第168天。
  • 第6个月重新招募参与者加强接种同种疫苗或安慰剂同剂量,110人纳入加强免疫:低剂量组38人、高剂量组35人、安慰剂组37人。

主要发现

  • 初免后28天ELISA EC90 GMT低剂量组682·7(95%CI 424·3-1098·5),高剂量组1305·7(970·1-1757·2);第168天分别降至197·9(107·9-362·7)和575·5(394·8-838·8),安慰剂组GMT为5·0且无特异性反应。
  • 加强后28天ELISA EC90滴度低剂量组升至6110(95%CI 4705-7935),高剂量组升至11825(8904-15705)。
  • 110名参与者中78人在加强后7天内报告至少一种征集性不良事件;两个疫苗组轻中度征集性不良事件发生率均显著高于安慰剂组。

临床怎么用

  • 作者认为结果支持采用加强接种策略以实现对埃博拉病毒病更持久的保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2013-15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a homologous vector in healthy adults in China. METHODS: In a randomised, double-blind, placebo-controlled, phase 1 clinical trial in one site in Jiangsu Province, China, 120 healthy adults aged 18-60 years received an initial dose of intramuscular adenovirus type-5 Ebola virus vaccine of 4·0 × 1010 viral particles, 1·6 × 1011 viral particles, or placebo, and were followed up to day 168. Participants were subsequently re-recruited to receive a booster dose of the same vaccine or placebo, in the same dose, at month 6. Women who were pregnant, breastfeeding, or planned to become pregnant during the next month were excluded. Randomisation was conducted by computer-generated block randomisation. Randomisation data were unmasked for interim analysis of the data obtained between days 0-28 but not disclosed to participants or site staff. Safety and immunogenicity analysis were done on the intention-to-treat population. We aimed to assess the safety profile of the experimental vaccine and the immunity responses to a single-dose immunisation or a homologous prime-boost regimen. Primary outcomes were Ebola glycoprotein-specific ELISA antibody responses 28 days post-boost and the occurrences of adverse reactions post-boost. The original trial and the extended booster study were registered with ClinicalTrials.gov, numbers NCT02326194 and NCT02533791, respectively. FINDINGS: Between Dec 28, 2014, and Jan 9, 2015, we enrolled 210 volunteers. 90 participants were not randomised due to not meeting inclusion criteria (61), meeting exclusion criteria (4), or withdrawal of consent (25). 120 people were randomly assigned to receive intramuscular Ebola vaccine at 4·0 × 1010 viral particles (low dose, n=40), Ebola vaccine at 1·6 × 1011 viral particles (high dose, n=40), or placebo (n=40, in two groups of 20). After prime vaccination, the geometric mean titer (GMT) of ELISA EC90 peaked at 682·7 (95% CI 424·3-1098·5) in the low-dose vaccine group and 1305·7 (970·1-1757·2) in the high-dose vaccine group at day 28, and then fell gradually through the next a few months to 575·5 (394·8-838·8) in the high-dose vaccine group and 197·9 (107·9-362·7) in the low-dose vaccine group at day 168. No specific response was recorded in the placebo group with a GMT of 5·0. Of the 120 participants involved in the initial trial, ten participants declined to participate, and 110 were included in the boost immunisation: 38 received the low dose, 35 received the high dose, and 37 received the placebo. At day 28 after boost vaccination, the ELISA EC90 titres rapidly rose to 6110 (95% CI 4705-7935) in the low-dose group and to 11825 (8904-15705) in the high dose group. 78 of 110 participants reported at least one solicited adverse reaction within the first 7 days after booster administration. Both of the groups who received vaccine showed significantly higher incidence of mild or moderate solicited adverse reactions than did the placebo group. INTERPRETATION: The adenovirus 5-vectored Ebola vaccine of 1·6 × 1011 viral particles was highly immunogenic and safe. The lower dose of 4·0 × 1010 viral particles was also safe, but immunogenicity seemed to be more vulnerable to the pre-existing immunity of adenovirus 5. A homologous priming-boosting regimen with adenovirus type-5 Ebola vaccine at 6 months interval was able to elicit greater antibody responses with longer duration. These results support an immunisation strategy to implement a booster injection for a more durable protection against Ebola virus disease. FUNDING: Chinese Ministry of Science and Technology and The National Health and Family Planning Commission, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Li JX, Hou LH, Meng FY, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2016. PMID: 28017642. doi:10.1016/S2214-109X(16)30367-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。